Teva (TEVA) Q4 FY25 earnings call

Teva delivered a strong Q4 and full-year 2025, driven by robust performance in its innovative portfolio and significant pipeline advancements. The company is successfully executing its 'Pivot to Growth' strategy, demonstrating consistent revenue growth and margin expansion, while also making substantial progress in deleveraging and advancing its R&D pipeline with multiple key milestones anticipated in 2026. Management remains confident in achieving its long-term financial targets.